Skip to content
drillr.ai

KNSA

Kiniksa Pharmaceuticals, Ltd.

NASDAQ · BMHealthcareBiotechnology
$62.58-2.14%

Price as of Jul 20, 2026

KNSA news

Kiniksa Pharmaceuticals, Ltd. news

A server-rendered, paginated timeline of the latest available company news.

  1. Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences

    LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (https://www.globenewswire.com/Tracker?data=PFddqFj96cwGm0rcpJr1XkYC9yiZU2sXkki04sxtQNi1exnJZ2X3G1GiTetNJdrgny5qTCJY6tQ5Uo7bwf-DtsDS05FEizqXX9Ioyc0uZ4z5u5anHnJJvJff_bwjIRk_hNo3_R89GYlNTMrP93tfs1NuQdYwLnmaUJR2eitClGUBGIsif3FMkSaz13voH9TmJnclIz1-PLGVEsHHQwVO4Cwinxdx7Ke001yfvzTml6d9xRFaIH9jLJYEr4-p-crn1JMbQT1NwD4qw_SNgiZWZIy5n4KSM8i6j9zo2MHlFCy0uR8PVIZKpFrYlwAHHE6yMljZBekppJDaHtP1YwOIaA==) (Nasdaq: KNSA) today annou

    Globe Newswire ·

  2. Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

    – ARCALYST(®) (rilonacept) Q1 2026 net product revenue of $214.3 million, representing 56% year-over-year growth – – ARCALYST 2026 expected net product revenue increased to $930 - $945 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026; Phase 3 pivotal trial expected to initiate by year-end – – Q1 2026 cash balance increased to $468.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, April 28, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceutic

    Globe Newswire ·

  3. Kiniksa Pharmaceuticals to Report First Quarter 2026 Financial Results on April 28, 2026

    LONDON, April 23, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (https://www.globenewswire.com/Tracker?data=3OkEUzLXuFKh086440LkeY_llVsfP71x_Z6Dj2-PNPiM3M2Pyas-mcjp0w1Y7b9lQkSABmiIk9gHDEb5Qq_Wv9g7oX48J9cLTSsIKJ1ho4bFOxuUwGb5OyPBSb5mp2-Z) (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 28, 2026 at 8:30 a.m. Eastern Time to report its first quarter 2026 financial results and recent portfolio execution. A live webcast will

    Globe Newswire ·

  4. Kiniksa Pharmaceuticals to Present at TD Cowen 46th Annual Health Care Conference

    For best results when printing this announcement, please click on link below: https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260225:nGNX9MW9SD&default-theme=true LONDON, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (https://www.globenewswire.com/Tracker?data=kw-rEmz7X49ora1f_kVOGu2Mq8A9BoJRBamaLZ7juiPKHRC1yLi7vS83kZCesbmYar7LQ-R1NuiItVjiNsYyOf9nVn17cZrErQMDXzf2oAW-7xRN7DAACuuLHDRO4i11_KdBa3JugKNeyxl0mYyParC-BtJX4Pxu_YqPGRj6TU2tjm

    Globe Newswire ·